VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
GALT
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
GALTGalectin Therapeutics Inc.
$2.98$196M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksGALTBalance Sheet

Galectin Therapeutics Inc. (GALT) Balance Sheet

26Y historyFree accessUpdated daily

Galectin's balance sheet appears structurally impaired, with $137.7M of total debt against just $14.8M in total assets (over 9.3x), negative $136.9M in shareholders' equity, a $446.8M accumulated deficit, and a current ratio that collapsed to 0.10 in 2026Q2 against $13.3M of cash.

Income StatementBalance SheetCash FlowRatios

GALT Balance Sheet

Annual statement

GALT Balance Sheet

Galectin Therapeutics Inc. (GALT) balance sheet — 26-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00
Total Current Assets12.9M19.44M17.25M27.71M20.55M41.82M29.46M48.21M8.83M3.82M15.79M26.4M29.66M10.69M9.52M6.5M6.2M304K380K1.39M5.94M4.69M10.82M7.7M1.99M1.57M210K
Cash & Short-Term Investments11.71M17.72M15.12M25.66M18.59M39.65M27.14M47.48M8.25M3.05M15.36M25.85M29.13M10.49M9.36M6.4M5.89M251K318K1.32M5.77M4.47M10.7M7.61M1.92M1.49M210K
Cash Only11.71M17.72M15.12M25.66M18.59M39.65M27.14M47.48M8.25M3.05M15.36M25.85M29.13M10.49M9.36M6.4M5.89M251K318K1.32M773K4.47M10.7M7.61M1.92M1.49M210K
Short-Term Investments000000000000000000005M000000
Accounts Receivable0000000000000000234K0000000000
Days Sales Outstanding---------------------------
Inventory000000000000000000000000000
Days Inventory Outstanding---------------------------
Other Current Assets1.2M1.72M2.13M2.05M1.96M2.17M2.32M729K579K6K6K6K6K00104K00000000080.77K0
Total Non-Current Assets104K96K243K490K733K7K135K258K174K342K1K8K16K26K44K111K105K132K324K393K427K269K286K305.73K289.2K194.61K20K
Property, Plant & Equipment00053K000000001K3K8K6K7K17K40K73K112K60K103K144K177.16K111.54K0
Fixed Asset Turnover---------------------------
Goodwill000000000000000000000000000
Intangible Assets00000000001K8K15K23K30K36K39K56K225K250K256K209K156K135K85.09K56.12K10K
Long-Term Investments000000000000000000000000000
Other Non-Current Assets104K96K243K437K733K7K135K258K174K342K00006K69K59K59K59K70K59K027K26.73K26.95K26.95K10K
Total Assets13.01M19.53M17.5M28.2M21.29M41.83M29.6M48.47M9.01M4.16M15.79M26.41M29.68M10.71M9.56M6.61M6.3M436K704K1.78M6.36M4.96M11.11M8M2.28M1.77M230K
Asset Turnover0.00x--------------------------
Asset Growth %73.19%11.64%-37.96%32.49%-49.11%41.31%-38.93%438.16%116.44%-73.66%-40.19%-11.02%177.02%12.05%44.6%4.95%1344.95%-38.07%-60.49%-71.99%28.21%-55.33%38.84%250.48%29.24%668.06%-
Total Current Liabilities46.41M8.03M35.41M15.68M13.01M9.03M5.4M2.82M2.11M2.97M3.78M1.36M1.7M2.49M1.64M2.21M1.77M1.05M1.08M2.6M5.99M1.38M1M378K666.79K550.7K180K
Accounts Payable3.5M3.25M5.66M6.43M3.89M1.8M1.29M1.66M297K608K910K448K906K762K397K384K125K221K447K601K340K295K206K166K302.9K236.22K80K
Days Payables Outstanding---------221.92K47.45K23.36K------3.33K3.43K1.85K------
Short-Term Debt33.21M021.12M000000000000000200K0000015K195K80K
Deferred Revenue (Current)3K00000000000000200K200K0000000000
Other Current Liabilities13.2M1.06M1.89M8.07M8.11M6.49M3.27M147K517K1.57M2.19M286K193K1.2M1.2M1.25M948K001.9M5.14M000174.25K020K
Current Ratio0.28x2.42x0.49x1.77x1.58x4.63x5.46x17.10x4.19x1.29x4.18x19.41x17.42x4.30x5.81x2.93x3.50x0.29x0.35x0.53x0.99x3.40x10.77x20.36x2.99x2.85x1.17x
Quick Ratio0.28x2.42x0.49x1.77x1.58x4.63x5.46x17.10x4.19x1.29x4.18x19.41x17.42x4.30x5.81x2.93x3.50x0.29x0.35x0.53x0.99x3.40x10.77x20.36x2.99x2.85x1.17x
Cash Conversion Cycle---------------------------
Total Non-Current Liabilities42K137.7M85.16M72.77M40.47M30.18M8K52K0000006K06.22M3.85M94K2.11M396K000000
Long-Term Debt0133.74M85.11M71.74M39.83M29.05M000000000000000000000
Capital Lease Obligations00020K00000000000000000000000
Deferred Tax Liabilities000000000000000000000000000
Other Non-Current Liabilities42K3.96M47K1M639K1.13M8K52K0000006K06.22M3.85M94K2.11M396K000000
Total Liabilities46.45M145.73M120.56M88.44M53.48M39.21M5.41M2.87M2.11M2.97M3.78M1.36M1.7M2.49M1.64M2.21M7.99M4.9M1.17M4.71M6.38M1.38M1M377.91K666.79K550.7K180K
Total Debt33.21M133.76M106.25M71.81M39.87M29.06M44K39K0000000000200K05.14M00015K195K80K
Net Debt21.5M116.04M91.13M46.15M21.28M-10.59M-27.1M-47.44M-8.25M-3.05M-15.36M-25.85M-29.13M-10.49M-9.36M-6.4M-5.89M-251K-118K-1.32M-773K-4.47M-10.7M-7.61M-1.91M-1.3M-130K
Debt / Equity-0.99x----11.11x0.00x0.00x----------------0.01x0.16x1.60x
Debt / EBITDA-2.92x--------------------------
Net Debt / EBITDA-1.89x--------------------------
Interest Coverage-1.45x-3.21x-7.49x-13.71x-36.54x-61.43x-268.71x-151.80x-40.37x-1352.92x----------25.95x-0.73x---1254.96x-7.85x--
Total Equity-33.44M-126.19M-103.07M-60.24M-32.19M2.62M24.19M45.59M6.9M1.19M12.02M25.05M27.97M8.23M7.92M4.4M-1.69M-4.47M-469K-2.92M-22K3.58M10.11M7.62M1.62M1.22M50K
Equity Growth %18.06%-22.44%-71.1%-87.12%-1330.66%-89.19%-46.94%560.99%478.21%-90.07%-52.03%-10.46%240.03%3.92%80.05%359.56%62.08%-852.45%83.96%-13190.91%-100.61%-64.54%32.54%371.68%32.94%2331.69%-
Book Value per Share-0.37-1.97-1.65-1.00-0.540.040.420.870.180.030.411.041.280.490.520.37-0.18-0.56-0.06-0.45-0.000.792.352.140.590.540.02
Total Shareholders' Equity-33.44M-126.19M-103.07M-60.24M-32.19M2.62M24.19M45.59M6.9M1.19M12.02M25.05M27.97M8.23M7.92M4.4M-1.69M-4.47M-469K-2.92M-22K3.58M10.11M7.62M1.62M1.22M50K
Common Stock100K65K62K61K59K59K56K56K41K36K33K28K22K18K16K13K64K52K48K40K32K27K27K019.03K15.52K10K
Retained Earnings-450.36M-432.55M-401.57M-354.37M-309.57M-270.69M-240M-216.39M-196.22M-181.17M-163.7M-140.05M-118.92M-101.97M-80.02M-69.14M-56.42M-47.72M-38.55M-35.16M-25.73M-26.43M-19.89M-12.71M-7.83M-4.16M-190K
Treasury Stock000000000000000000000000000
Accumulated OCI0000000000000000-309K-299K-276K00-257K-1K-70K-204.96K-91.58K0
Minority Interest000000000000000000000000000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Debt Exceeds Assets Tenfold

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Asset Base Eroding Under Debt Load

According to Galectin's reported balance sheets, total assets contracted 43% from $25.9M in 2024Q1 to $14.8M in 2026Q2 while total liabilities rose 56% to $151.7M, producing a $136.9M equity deficit that signals structurally impaired balance sheet quality.

The trajectory is unambiguously deteriorating: equity has worsened from -$71.1M to -$136.9M over ten quarters, a 93% deepening driven by both the $55.2M increase in total debt and the $11.1M decline in assets. This is not a temporary working-capital swing but a structural imbalance where accumulated deficits compound faster than any asset base the company retains, consistent with the zero-revenue profile identified in the income statement analysis. Investors should note that without a revenue or financing inflection, this trajectory suggests further balance sheet impairment ahead.

Debt Surpasses Total Assets by Ninefold

Based on Galectin's reported figures, total debt reached $137.7M in 2026Q2 against just $14.8M in total assets, representing a debt-to-asset ratio exceeding 9.3x and implying that creditors' claims dwarf the entire asset base by nearly $123M.

The debt build from $82.5M to $137.7M over ten quarters has occurred without any corresponding asset growth, suggesting the financing is funding operating losses rather than productive investment—a pattern typical of convertible-note-dependent biotechs. With no disclosed interest coverage capability from revenue and cash burn still active, the refinancing risk warrants close attention, as the debt appears to be the dominant liability class consuming the balance sheet. The absence of a debt maturity schedule in this dataset means investors should examine the filing for near-term conversion or repayment triggers that could accelerate dilution or default risk.

Current Ratio Collapsed to Danger Zone

As reported in Galectin's quarterly balance sheets, the current ratio plunged from 2.15 in 2026Q1 to 0.10 in 2026Q2, and cash fell to $13.3M against $151.7M in total liabilities, indicating that near-term obligations exceed liquid resources by an order of magnitude.

The sudden current ratio collapse from 2.15 to 0.10 between consecutive quarters is the most alarming liquidity signal in the dataset, suggesting a large current-portion liability was reclassified or a significant debt tranche matured into current status. With cash of $13.3M covering less than 9% of total liabilities and quarterly operating cash outflows still running in the low millions per the cash flow analysis, the buffer against a financing delay appears thin. This combination of a shrinking cash balance and a deteriorating current ratio suggests Galectin is approaching a liquidity inflection point where new financing or restructuring becomes urgent rather than discretionary.

Accumulated Deficit Swallows Negative Equity

According to Galectin's balance sheet disclosures, accumulated losses reached $446.8M as of 2026Q2 against negative shareholders' equity of $136.9M, implying that historical write-downs and financing costs have consumed the entire book value plus an additional $136.9M in creditor-funded obligations.

The $80.9M increase in accumulated deficit over ten quarters far outpaces the $65.8M deterioration in equity, indicating that new debt issuance—likely at a discount or with attached warrants—has partially funded operations while simultaneously eroding per-share book value. The absence of goodwill or meaningful PPE on the balance sheet means there are no tangible assets to liquidate in a downside scenario, leaving convertible debt holders and equity holders competing over a shrinking cash pool. This equity profile implies that common shareholders hold an extremely deep out-of-the-money claim, consistent with the pure-pipeline optionality thesis from the income statement analysis.

Negative Working Capital Masks Convertible Structure

Based on Galectin's reported balance sheets, the $137.7M debt load against $151.7M in liabilities and only $14.8M in assets may understate true economic leverage if the convertible notes carry embedded derivative liabilities or anti-dilution provisions not separately itemized in this summary data.

The most non-obvious risk is that headline leverage metrics may be misleading if a substantial portion of the reported debt is convertible notes with equity-linked features that could trigger massive dilution upon conversion—dilution that would not appear as a liability on the balance sheet but would devastate remaining equity holders. Additionally, the current ratio swing from 2.15 to 0.10 in a single quarter warrants investigation: it may indicate covenant breaches, accelerated repayment demands, or note conversions that could further constrain liquidity. Investors should examine the full 10-Q footnote disclosures for contingent conversion triggers, warrant overhang, and any going-concern language, as these off-summary-sheet features often determine survival outcomes for pre-revenue biotechs in this leverage position.

GALT — Frequently Asked Questions

Quick answers to the most common questions about buying GALT stock.

What are the total assets of Galectin Therapeutics Inc. (GALT)?

As of 2025, Galectin Therapeutics Inc. (GALT) had total assets of $19.5M including $19.4M in current assets.

How much debt does Galectin Therapeutics Inc. (GALT) have?

Galectin Therapeutics Inc. (GALT) carries total debt of $133.8M, offset by $17.7M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Galectin Therapeutics Inc.?

Galectin Therapeutics Inc. (GALT) has total shareholders' equity (book value) of $-126.2M ($-1.97 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Galectin Therapeutics Inc.'s current ratio and liquidity?

Galectin Therapeutics Inc. (GALT) reported a current ratio of 2.42x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.